Title: Chemotherapy of respiratory syncytial virus infections: the final breakthrough
Authors: De Clercq, Erik # ×
Issue Date: Mar-2015
Publisher: Elsevier Science Publishers
Series Title: International Journal of Antimicrobial Agents vol:45 issue:3 pages:234-237
Article number: S0924-8579(15)00048-5
Abstract: Respiratory syncytial virus (RSV) infection is the leading cause of hospitalisation for children under 5 years of age and causes excess mortality in the elderly. There is still no approved vaccine available, although the disease can be curtailed by RSV-specific monoclonal antibody. The only antiviral drug approved for the treatment of RSV infection is ribavirin aerosol, but this treatment is cumbersome and its efficacy is questionable. A new antiviral, GS-5806, which interferes with virus-cell fusion, has proven efficacious in experimental RSV infections in adults.
ISSN: 0924-8579
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Virology and Chemotherapy (Rega Institute)
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
2015037.pdf Published 1069KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science